Healthcare / Pharmaceutical RetailersHKSE
$2.26
-0.01 (-0.44%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $159.6M · quality 50.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
51/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.6B
P/E
18.8x
↓EV/EBITDA
13.9x
↑ROE
10.9%
↑Gross Margin
48.9%
↑Debt/Equity
0.12
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-6.2%
FCF CAGR
+111.4%
FCF margin
14.0%
FCF / Net income
1.57x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.28B · net income $114.4M · FCF $179.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.28B | $1.28B | $1.53B | $1.57B | $1.56B |
| Net Income | $114.4M | $114.4M | $151.6M | $138.5M | $235.3M |
| EBITDA | $184.2M | $184.2M | $246.5M | $191.8M | $309.8M |
| EPS | 0.10 | 0.10 | 0.13 | 0.12 | 0.20 |
| Gross Margin | 48.9% | 48.9% | 44.6% | 42.7% | 50.2% |
| Operating Margin | 11.3% | 11.3% | 14.6% | 11.5% | 15.4% |
| Net Margin | 8.9% | 8.9% | 9.9% | 8.8% | 15.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.12 | 0.12 | 0.07 | 0.07 | 0.04 |
| Current Ratio | 3.22 | 3.22 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $179.3M | $179.3M | $159.6M | $-163.2M | $19.0M |
| Returns | |||||
| ROE | 10.9% | 10.9% | 13.7% | 13.8% | 23.3% |
| Valuation | |||||
| P/E | 18.83 | 18.83 | 18.08 | 15.50 | 10.90 |
| EV/EBITDA | 13.90 | 13.90 | 10.98 | 11.22 | 7.81 |
| P/B | 2.48 | 2.48 | 2.46 | 2.18 | 2.58 |
| Growth & Yield | |||||
| Revenue Growth | -16.2% | -16.2% | -2.3% | 0.7% | — |
| EPS Growth | -23.1% | -23.1% | 8.3% | -40.0% | — |
| Dividend Yield | 4.8% | 4.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
26.1%
EPS terminal req.
$0.20
Spread vs growth
-49.2%
5Y implied EPS CAGR
19.4%
EPS terminal req.
$0.24
Spread vs growth
-42.5%
10Y implied EPS CAGR
14.6%
EPS terminal req.
$0.39
Spread vs growth
-37.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+9.4%
Start / end P/E
16.6x → 22.6x
EPS bridge
0.13 → 0.10
Residual
-8.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.